FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980080213> ?p ?o ?g. }

• W1980080213 endingPage "471" @default.
• W1980080213 startingPage "466" @default.
• W1980080213 abstract "Background: Treatment with biological response modifiers such as interferons resulted in reproducible responses in patients with renal cell carcinoma without proved benefit on survival and quality of life. Two trials were conducted to define the efficacy and the benefit on survival of interferons in the treatment of advanced renal cell carcinoma. Patients and Methods: Prospectively, 81 patients were treated subcutaneously (sc.) with interferon-α 2B (IFN-α) or interferon-γ (IFN--y). The first trial was randomized; 30 patients received weekly 200 µg IFN-γ alone, and 30 patients were treated with a combination of IFN-α 2B (3-6 ×106 IU/m² 3 times weekly) and interleukin-2 (IL-2) (4.8-19.2 ×106 IU/m² 5 times weekly) for 6 weeks. In the second trial, 21 patients received IFN-α 2B (10 × 10^-6 IU sc.) combined with gradually escalating doses (15-300 µg sc.) of granulocyte-macrophage colony-stimulating factor (GM-CSF) 3 times weekly for 12 weeks. Results: The overall response proportion was 12% (5 complete and 4 partial responses; CR, PR). In the patient groups treated with IFN-α 2B, the overall response rate increased up to 20%. The median response duration was 10.2 months. The median survival duration was 12.7 months. A univariate statistical analysis on prognostic factors (age, sex, Karnofsky performance status, prior nephrectomy, lung metastases only, treatment regimen) showed that only prior nephrectomy was a significant prognostic factor for survival. Conclusion: Biological response modifiers such as IFN-α or IFN-γ had minimal antitumorigenic activity in patients with renal cell carcinoma. Combination therapies with IFN-α 2B resulted in significant higher response rates, but this did not translate into prolonged survival. Out of these studies only prior nephrectomy was identified as the predictor of long-term survival. Because of these disappointing results the study of new biological response modifiers remains priority." @default.
• W1980080213 created "2016-06-24" @default.
• W1980080213 creator A5003311439 @default.
• W1980080213 creator A5021158336 @default.
• W1980080213 creator A5036829869 @default.
• W1980080213 creator A5066385499 @default.
• W1980080213 creator A5082873250 @default.
• W1980080213 date "1997-01-01" @default.
• W1980080213 modified "2023-09-27" @default.
• W1980080213 title "Interferon-α and Interferon–γ in Advanced Renal Cell Carcinoma: Treatment Results, Survival, and Prognostic Factors in 81 Patients" @default.
• W1980080213 doi "https://doi.org/10.1159/000219009" @default.
• W1980080213 hasPublicationYear "1997" @default.
• W1980080213 type Work @default.
• W1980080213 sameAs 1980080213 @default.
• W1980080213 citedByCount "3" @default.
• W1980080213 countsByYear W19800802132015 @default.
• W1980080213 crossrefType "journal-article" @default.
• W1980080213 hasAuthorship W1980080213A5003311439 @default.
• W1980080213 hasAuthorship W1980080213A5021158336 @default.
• W1980080213 hasAuthorship W1980080213A5036829869 @default.
• W1980080213 hasAuthorship W1980080213A5066385499 @default.
• W1980080213 hasAuthorship W1980080213A5082873250 @default.
• W1980080213 hasConcept C126322002 @default.
• W1980080213 hasConcept C143998085 @default.
• W1980080213 hasConcept C203014093 @default.
• W1980080213 hasConcept C2776178377 @default.
• W1980080213 hasConcept C2777472916 @default.
• W1980080213 hasConcept C2777546739 @default.
• W1980080213 hasConcept C2781228144 @default.
• W1980080213 hasConcept C2909179924 @default.
• W1980080213 hasConcept C3019579692 @default.
• W1980080213 hasConcept C71924100 @default.
• W1980080213 hasConceptScore W1980080213C126322002 @default.
• W1980080213 hasConceptScore W1980080213C143998085 @default.
• W1980080213 hasConceptScore W1980080213C203014093 @default.
• W1980080213 hasConceptScore W1980080213C2776178377 @default.
• W1980080213 hasConceptScore W1980080213C2777472916 @default.
• W1980080213 hasConceptScore W1980080213C2777546739 @default.
• W1980080213 hasConceptScore W1980080213C2781228144 @default.
• W1980080213 hasConceptScore W1980080213C2909179924 @default.
• W1980080213 hasConceptScore W1980080213C3019579692 @default.
• W1980080213 hasConceptScore W1980080213C71924100 @default.
• W1980080213 hasIssue "6" @default.
• W1980080213 hasLocation W19800802131 @default.
• W1980080213 hasOpenAccess W1980080213 @default.
• W1980080213 hasPrimaryLocation W19800802131 @default.
• W1980080213 hasRelatedWork W2021256410 @default.
• W1980080213 hasRelatedWork W2074722385 @default.
• W1980080213 hasRelatedWork W2122157810 @default.
• W1980080213 hasRelatedWork W2316507190 @default.
• W1980080213 hasRelatedWork W2333389543 @default.
• W1980080213 hasRelatedWork W2409509982 @default.
• W1980080213 hasRelatedWork W2463178207 @default.
• W1980080213 hasRelatedWork W2774592062 @default.
• W1980080213 hasRelatedWork W4242253897 @default.
• W1980080213 hasRelatedWork W2739301355 @default.
• W1980080213 hasVolume "20" @default.
• W1980080213 isParatext "false" @default.
• W1980080213 isRetracted "false" @default.
• W1980080213 magId "1980080213" @default.
• W1980080213 workType "article" @default.